IP Library › Granted Patent US 8,927,002
Granted Patent B2
US 8,927,002 · App. 12/477,093 · Granted Jan 6, 2015

Stent with a coating or a basic body containing a lithium salt and use of lithium salts for prevention of restenosis

Inventor: Eric Wittchow (Nuremberg, DE)
Assignee: Biotronik VI Patent AG
A61L31/148A61L31/028A61L31/088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,002
App. No.
12/477,093
Granted
Jan 6, 2015
Kind
B2
Abstract

The invention relates to a stent with in particular a coated basic body made of an implant material the use of lithium salts as a coating material or a component of an implant material for stents and the use of lithium salts in a method for restenosis prevention. The inventive stent having a basic body made of an implant material is characterized in that (i) the basic body has a coating which comprises or consists of a lithium salt, and/or (ii) the implant material is biocorrodible and the basic body contains a lithium salt.

Claims (15)

1. A cardiovascular stent having a basic body of an implant material, characterized in that

the basic body is coated with a coating consisting of a lithium salt for localized delivery of lithium ions, wherein the lithium salt is selected from the group consisting of lithium carbonate, lithium bicarbonate, lithium hydroxide, lithium nitride and a lithium salt of a carboxylic acid compound.

2. The stent according to claim 1 , wherein the implant material comprises a biocorrodible material and a lithium salt.

3. The stent according to claim 1 , wherein the lithium salt is basic.

4. The stent according to claim 1 , wherein the implant material is a biocorrodible magnesium alloy.

5. The stent according to claim 1 , wherein the localized delivery provides a localized lithium ion concentration of 5 to 30 mmol/liter.

6. The stent according to claim 1 , wherein the basic body comprises more than 1 wt % and less than or equal to 15 wt % of lithium ions.

7. The stent according to claim 1 , wherein lithium content is from 5 to 200 μg per mm stent length.

8. The stent according to claim 1 , wherein entire surface of the basic body of the stent is covered by the coating.

9. The stent according to claim 1 , wherein the stent is configured to deliver the lithium salt in an amount sufficient to stop a cell cycle in the S-phase at a stented lesion.

10. A cardiovascular stent, the stent having a basic body formed from a biocorrodible magnesium alloy and coated with a coating consisting essentially of a lithium salt dispersed in a polymeric carrier matrix, wherein the lithium salt is selected from the group consisting of lithium carbonate, lithium bicarbonate, lithium hydroxide, lithium nitride and a lithium salt of a carboxylic acid compound, further wherein the basic body comprises more than 1 wt % and less than or equal to 15 wt % of lithium ions.

11. The stent according to claim 10 , wherein the coating comprises at least 10% lithium salt.

12. The stent according to claim 11 , wherein the coating comprises at least 30% lithium salt.

13. The stent according to claim 10 , wherein the body comprises 15 wt % lithium ions.

14. The stent according to claim 10 , wherein the lithium salt is the lithium carboxylate, optionally selected from the group consisting of lithium formate, lithium acetate, lithium lactate, lithium glycinate and lithium bis(oxalto)borate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2018
From: BIOTRONIK VI PATENT AG
To: BIOTRONIK AG
Reel/Frame 045853/0610 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2009
From: WITTCHOW, ERIC, DR.
To: BIOTRONIK VI PATENT AG
Reel/Frame 022770/0517 →
Priority Claims (1)
DE 10 2008 002 471 · Jun 17, 2008 · national
Continuity (1)
Related Publication 20090311300A1 · Dec 17, 2009